Five-year data shows lasting benefit for patients with advanced gastroesophageal cancers treated with nivolumab and chemotherapy.

Nivolumab plus chemotherapy improved long-term survival in Chinese patients with advanced gastric, GEJ, or esophageal cancer.

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...

The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...

Datopotamab deruxtecan-dlnk received approval from the FDA for previously treated unresectable or metastatic, HR-positive, HER2-negative breast cancer. The FDA granted approval to datopotamab ...

Findings from an exploratory 2a study showed improvements in patients with cancer cachexia with PH284 compared with placebo. PH284, an investigational pherine nasal spray, showed improvements in the ...

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...